ALKS
Price
$29.94
Change
+$1.02 (+3.53%)
Updated
Sep 5 closing price
Capitalization
4.94B
46 days until earnings call
PAHC
Price
$39.45
Change
+$0.38 (+0.97%)
Updated
Sep 5 closing price
Capitalization
1.6B
60 days until earnings call
Interact to see
Advertisement

ALKS vs PAHC

Header iconALKS vs PAHC Comparison
Open Charts ALKS vs PAHCBanner chart's image
Alkermes
Price$29.94
Change+$1.02 (+3.53%)
Volume$2.5M
Capitalization4.94B
Phibro Animal Health
Price$39.45
Change+$0.38 (+0.97%)
Volume$480.72K
Capitalization1.6B
ALKS vs PAHC Comparison Chart in %
Loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. PAHC commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Buy and PAHC is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ALKS: $29.94 vs. PAHC: $39.45)
Brand notoriety: ALKS and PAHC are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALKS: 141% vs. PAHC: 145%
Market capitalization -- ALKS: $4.94B vs. PAHC: $1.6B
ALKS [@Pharmaceuticals: Generic] is valued at $4.94B. PAHC’s [@Pharmaceuticals: Generic] market capitalization is $1.6B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 1 FA rating(s) are green whilePAHC’s FA Score has 1 green FA rating(s).

  • ALKS’s FA Score: 1 green, 4 red.
  • PAHC’s FA Score: 1 green, 4 red.
According to our system of comparison, PAHC is a better buy in the long-term than ALKS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 6 TA indicator(s) are bullish while PAHC’s TA Score has 5 bullish TA indicator(s).

  • ALKS’s TA Score: 6 bullish, 3 bearish.
  • PAHC’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ALKS is a better buy in the short-term than PAHC.

Price Growth

ALKS (@Pharmaceuticals: Generic) experienced а +3.35% price change this week, while PAHC (@Pharmaceuticals: Generic) price change was +6.77% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Reported Earning Dates

ALKS is expected to report earnings on Oct 22, 2025.

PAHC is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALKS($4.94B) has a higher market cap than PAHC($1.6B). PAHC has higher P/E ratio than ALKS: PAHC (33.15) vs ALKS (14.46). PAHC YTD gains are higher at: 90.357 vs. ALKS (4.103). ALKS has higher annual earnings (EBITDA): 450M vs. PAHC (147M). ALKS has less debt than PAHC: ALKS (72.7M) vs PAHC (762M). ALKS has higher revenues than PAHC: ALKS (1.51B) vs PAHC (1.3B).
ALKSPAHCALKS / PAHC
Capitalization4.94B1.6B309%
EBITDA450M147M306%
Gain YTD4.10390.3575%
P/E Ratio14.4633.1544%
Revenue1.51B1.3B116%
Total Cash1.02BN/A-
Total Debt72.7M762M10%
FUNDAMENTALS RATINGS
ALKS vs PAHC: Fundamental Ratings
ALKS
PAHC
OUTLOOK RATING
1..100
2123
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
29
Undervalued
PROFIT vs RISK RATING
1..100
3637
SMR RATING
1..100
3949
PRICE GROWTH RATING
1..100
5936
P/E GROWTH RATING
1..100
27100
SEASONALITY SCORE
1..100
n/a49

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAHC's Valuation (29) in the Pharmaceuticals Major industry is significantly better than the same rating for ALKS (97) in the Biotechnology industry. This means that PAHC’s stock grew significantly faster than ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (36) in the Biotechnology industry is in the same range as PAHC (37) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew similarly to PAHC’s over the last 12 months.

ALKS's SMR Rating (39) in the Biotechnology industry is in the same range as PAHC (49) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew similarly to PAHC’s over the last 12 months.

PAHC's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as ALKS (59) in the Biotechnology industry. This means that PAHC’s stock grew similarly to ALKS’s over the last 12 months.

ALKS's P/E Growth Rating (27) in the Biotechnology industry is significantly better than the same rating for PAHC (100) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew significantly faster than PAHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSPAHC
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
71%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
56%
Bearish Trend 1 day ago
61%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
72%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
70%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 1 day ago
72%
Declines
ODDS (%)
Bearish Trend 12 days ago
62%
Bearish Trend 5 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
57%
Bearish Trend 1 day ago
69%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HISIX10.93N/A
N/A
Homestead International Equity
GVEYX19.64N/A
N/A
GuideStone Funds Value Equity Instl
FGILX23.83N/A
N/A
Fidelity Global Equity Income
BEXUX18.24N/A
N/A
Baron Emerging Markets R6
GSILX21.54N/A
N/A
Goldman Sachs GQG Ptnrs Intl Opps C

ALKS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALKS has been loosely correlated with AMRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ALKS jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
+3.53%
AMRX - ALKS
39%
Loosely correlated
+0.73%
COLL - ALKS
36%
Loosely correlated
-2.32%
PRGO - ALKS
33%
Poorly correlated
-2.75%
PAHC - ALKS
32%
Poorly correlated
+0.97%
PCRX - ALKS
32%
Poorly correlated
-1.05%
More

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with AMRX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
+0.97%
AMRX - PAHC
48%
Loosely correlated
+0.73%
PBH - PAHC
42%
Loosely correlated
-2.55%
ZTS - PAHC
41%
Loosely correlated
+0.08%
ELAN - PAHC
39%
Loosely correlated
+5.50%
COLL - PAHC
36%
Loosely correlated
-2.32%
More